Use of intravenous heparin by North American neurologists: do the data matter?
نویسندگان
چکیده
BACKGROUND AND PURPOSE Our aim was to determine current usage patterns of intravenous heparin for patients with acute ischemic stroke. METHODS A survey was undertaken of 280 neurologists from the United States and 270 neurologists from Canada. Brief vignettes were presented for the following 5 scenarios: stroke in evolution, atrial fibrillation-related stroke (A FIB), vertebrobasilar stroke, carotid territory stroke, and multiple transient ischemic attacks. The effect of medicolegal factors was also ascertained. Statistical comparisons were done with chi-squared testing. RESULTS US neurologists were significantly more likely than Canadian neurologists to use intravenous heparin for patients with stroke in evolution (51% versus 33%, P<0.001), vertebrobasilar stroke (30% versus 8%, P<0.001), carotid territory stroke (31% versus 4%, P<0.001), and multiple transient ischemic attacks (47% versus 9%, P<0.001). The vast majority of US and Canadian neurologists would use intravenous heparin for acute stroke patients with A FIB (88% and 84%, respectively). US neurologists more often cited medicolegal factors as a potential influence on the decision-making process than Canadian neurologists (33% versus 10%, P<0.001). CONCLUSIONS In several clinical scenarios, US neurologists were significantly more likely than Canadian neurologists to use intravenous heparin. Fears regarding medicolegal consequences may partially explain the treatment disparity. Despite the publication of 4 clinical trials, which have not shown any long-term benefit for patients with acute stroke and A FIB (International Stroke Trial, Heparin in Acute Embolic Stroke Trial) or cardioembolic stroke (Trial of Org 10172 in Acute Stroke Treatment, the Tinzaparin in Acute Ischemic Stroke Trial), both US and Canadian neurologists would use intravenous heparin in large numbers for this condition. Further studies are warranted to investigate the lack of impact of "negative" studies on clinician behavior.
منابع مشابه
Risk Factors for Leukoaraiosis in North American and Iranian Stroke Patients
Background: Leukoaraiosis (LA) or white matter thinning and rarefaction are common in stroke patients. This pilot double-center study was designed to evaluate LA risk factors in stroke patients. Methods: This cross sectional study was conducted on 100 consecutive stroke patients in Walter Mackenzie Hospital, Canada and 100 consecutive stroke patients in Valie-Asr Hospital, Iran in 2004. Diagnos...
متن کاملHeparin Resistance During and Post-Intravenous Nitroglycerin Infusion
Nitroglycerin has been reported to reduce activated partial thromboplastin time (aPTT) values in patients treated with concurrent heparin and nitroglycerin. However, studies have yielded conflicting results. To determine whether intravenous nitroglycerin alters the anticoagulant effect of heparin, we prospectively evaluated twenty patients admitted for coronary angioplasty by measurin...
متن کاملبروز ترومبوسیتوپنی ناشی ازهپارین، در دو روش تجویز داخل وریدی در بیماران با سندرم حاد کرونری
Incidence of Thrombocytopenia Induced by Two Methods of Intravenous Heparin injection in Patients with Acute Coronary Syndrome. H. Nough MD1* , A. Khodadadi Zadeh MSc2, M. Aref 3, A. Esmaieli Nadimi MD1 1- Assisstant Professor of Cardiology, University of Medical Sciences, Rafsanjan, Iran 2- Academic Member, Dept. of Nursing, Faculty of Nursing Midwifery, University of Medical Sci...
متن کاملمقایسه توپوگرافی تنگی قلمروکاروتید در بیماران سکته مغزی با دو نژاد آمریکای شمالی و ایرانی
Introduction: Atherosclerotic stenosis of carotid territory is the most common cause of ischemic stroke. A higher frequency of intracranial arterial stenosis has been reported in Africa and the Far East. Methods: 304 geriatric ischemic stroke patients admitted in Mackenzie hospital, Canada and the same number of geriatric ischemic stroke patients with similar sex ratio admitted in Valie-Asr ho...
متن کاملPreparation, properties and preclinical pharmacokinetics of low molecular weight heparin-modified isoliquiritigenin-loaded solid lipid nanoparticle
Low molecular weight heparin-modified isoliquiritigenin-loaded solid lipid nanoparticle (LMWH-ISL-SLN) was developed for injective application. The morphological observation, particle diameter and zeta potential of LMWH-ISL-SLN were characterized using transmission electron microscopy (TEM) and a Malvern Zetasizer. Its entrapment efficiency (EE) and drug loading (DL) were determined by ultracen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Stroke
دوره 33 6 شماره
صفحات -
تاریخ انتشار 2002